Novartis enters agreement to acquire Mariana Oncology, strengthening radioligand therapy pipeline
arcticnovartis
Thu, 05/02/2024 – 13:04
Read more about Novartis enters agreement to acquire Mariana Oncology, strengthening radioligand therapy pipel…
Novartis and Medicines for Malaria Venture announce positive efficacy and safety data for a novel treatment for babies
Novartis radioligand therapy Lutathera® FDA approved as first medicine specifically for pediatric patients with gastroenteropancreatic neuroendocrine tumors
arcticnovartis
Tue, 04/23/2024 – 19:49
Read more about Novartis radioligand therapy Lutat…
Novartis delivers double-digit sales growth and core margin expansion in Q1; FY 2024 guidance raised
arcticnovartis
Tue, 04/23/2024 – 07:04
Read more about Novartis delivers double-digit sales growth and core margin expansion in Q1; FY 2024 guidan…
Novartis, au premier trimestre: croissance à deux chiffres du chiffre d’affaires et expansion de la marge core; hausse des prévisions pour 2024
arcticnovartis
Tue, 04/23/2024 – 07:04
Read more about Novartis, au premier trimestre: croissance à deu…
Novartis erzielt im ersten Quartal ein zweistelliges Umsatzwachstum und steigert die Kerngewinnmarge; Prognose für das Geschäftsjahr 2024 erhöht
arcticnovartis
Tue, 04/23/2024 – 07:04
Read more about Novartis erzielt im ersten Quartal ein zweistel…
Novartis Kesimpta® six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis
arcticnovartis
Wed, 04/17/2024 – 07:19
Read more about Novartis Kesimpta® six-year efficacy data sh…
New Novartis Fabhalta® (iptacopan) data show clinically meaningful and statistically significant proteinuria reduction of 38.3% versus placebo for patients with IgA nephropathy (IgAN)
arcticnovartis
Mon, 04/15/2024 – 20:04
Read more about New Nova…
Novartis tender offer for MorphoSys AG commences
arcticnovartis
Thu, 04/11/2024 – 10:24
Read more about Novartis tender offer for MorphoSys AG commences
Basel, April 11, 2024 – Novartis published today the offer document for the vo…
New Novartis data show early addition of twice-yearly* Leqvio® (inclisiran) following maximally tolerated statin therapy significantly reduces LDL-C in ASCVD patients in real-world setting
arcticnovartis
Sat, 04/06/2024 – 22:19
Read more about New…